AstraZeneca signs mRNA manufacturing deal with China's CanSino
WEBAug 9, 2023 · Under the deal, CanSino will use its mRNA manufacturing platform to support AZ on the R&D of certain vaccines, the filing shows. The pair may further collaborate on R&D and commercialization in...
China's CanSino in mRNA vaccine deal with AstraZeneca
WEBSHANGHAI, Aug 8 (Reuters) - CanSino Biologics (6185.HK) has agreed with AstraZeneca (AZN.L) to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's...
AstraZeneca signs vaccine deal with China’s CanSino - Financial Times
WEBAug 9, 2023 · AstraZeneca has signed a deal with Chinese pharmaceutical company CanSino Biologics to develop potential messenger RNA vaccines, as the Anglo Swedish company expands its work to include the...
China's CanSino seeks more vaccine contracts after AstraZenca deal
WEBAug 31, 2023 · AstraZeneca said the deal would support investigational mRNA vaccines early in its pipeline, but the companies have declined to provide any further details.
The CanSino Biologics Ad5-nCoV-S [recombinant] COVID-19 vaccine…
WEBJun 10, 2022 · The CanSino Biologics Ad5-nCoV-S [recombinant] COVID-19 vaccine: What you need to know. 10 June 2022. The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued updated interim policy recommendations for the use of the Ad5-nCoV-S recombinant (Ad5-nCoV) vaccine against COVID-19.
China's CanSino seeks more vaccine contracts after AstraZenca deal
WEBAug 31, 2023 · China's CanSino Biologics, which recently announced a contract manufacturing deal to support AstraZenca's messenger RNA (mRNA) technology vaccine programme, is in talks with more firms on...
Final efficacy analysis, interim safety analysis, and immunogenicity …
WEBJan 15, 2022 · The Ad5-nCoV vaccine (CanSino Biologics, Tianjin, China) uses the replication-defective, human adenovirus type 5 as a vector expressing the S protein of SARS-CoV-2 (ancestral strain; NC_045512.2) which is produced in HEK293SF-3F6 cells.
AstraZeneca set to make one of its first acquisitions in China
WEBDec 26, 2023 · In August, AstraZeneca signed a deal with China’s CanSino Biologics for the production of its potential mRNA vaccines. In November, the drugmaker announced a licensing agreement with...
CanSino Biologics: World’s first inhaled Covid vaccine approved in ...
WEBSep 6, 2022 · The vaccine maker, CanSino Biologics, said in a statement Sunday that China’s medicines regulator had approved the inhaled dose for emergency use as a booster vaccine. The product, known as ...
China's CanSino in mRNA vaccine deal with AstraZeneca - ET …
WEBAug 9, 2023 · Shanghai: CanSino Biologics has agreed with AstraZeneca to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the …
Skip to content